PF
Therapeutic Areas
Capricor Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Deramiocel (CAP-1002) | Duchenne Muscular Dystrophy (DMD) | Phase 3 |
| StealthX™ Vaccine Platform | Infectious Disease / Oncology (Undisclosed) | Preclinical |
| StealthX™ Therapeutic Delivery Platform | Multiple (Undisclosed) | Preclinical |
Leadership Team at Capricor Therapeutics
LM
Linda Marbán, Ph.D.
Chief Executive Officer and Director
FL
Frank Litvack M.D., FACC
Executive Chairman
MB
Michael Binks, M.D.
Chief Medical Officer
KA
Kristi A. H. Elliott, Ph.D.
Chief Operating & Science Officer
PG
Paul G. Auwaerter, M.D., M.B.A., FIDSA
Director
CM
Craig McDonald, M.D.
Scientific Advisor (DMD), University of California at Davis
ME
Michelle Eagle, Ph.D., M.Sc., MCSP
Scientific Advisor (DMD), Atom International Ltd
TF
Timothy Franson, M.D., FACP, FIDSA
Scientific Advisor (DMD), Faegre Drinker Biddle & Reath LLP
MT
Michael Taylor, M.D., Ph.D.
Scientific Advisor (DMD), Texas Children’s Hospital
EM
Eugenio Mercuri, M.D.
Scientific Advisor (DMD), Catholic University of the Sacred Heart